Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2019-09-12

Imcyse to present positive results in EAE model of multiple sclerosis at ECTRIMS 2019

2019-08-27

Imcyse reports successful first-in-human phase 1B study in type 1 diabetes with IMCY-0098

2019-08-05

Imcyse announces changes in management and board, appoints Thomas Taapken as Executive Chairman

2019-06-18

Imcyse secures total of €35M in Series B financing round and additional grants

Go Back